Stifel on Insmed (INSM): Topline data disclosure removes potential NT downside risk

March 23, 2026 8:06 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $205.00 price target on Insmed (NASDAQ: INSM)The analyst commented, "Arikayce Appears ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found